Orphazyme ADS holders given July deadline

After July 11, the Bank of New York Mellon can choose to sell the underlying shares.

Photo: Nikolaj Skydsgaard/REUTERS / X07081

The owners of Orphazyme’s American Depository Shares (ADSs), which are evidenced by American Depository Receipts (ADRs), must contact the Bank of New York Mellon, which owns the underlying shares, before July 11, the firm writes in a press release.

After that date, ADR owners can pay a set fee of USD 17.50 plus an extra charge of up to USD 0.05 per ADR to for the underlying shares.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs